STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Why only for healthcare professionals?

The content on these information pages is directed solely at you if you are a doctor, nurse, or pharmacist, as it concerns treatment with prescription medicines.

Please confirm that you are a healthcare professional (healthcare assistant, nurse, doctor, psychologist, or other licensed healthcare professional).

Back to main page

Confirm and continue

Yazen raises €19.5m to expand its GLP-1-based obesity treatment across Europe, aiming to provide digital health solutions with lifestyle support for effective weight loss.

Yazen secures €19.5m Series A to expand GLP-1-based obesity treatment across Europe - article in Sifted

Swedish healthtech startup Yazen, specialising in GLP-1 weight-loss and diabetes medications combined with lifestyle support, has raised €19.5 million in Series A funding. Led by Evli Growth Partners and Helsana HealthInvest, this is the largest funding round for a European startup in this field to date. Yazen, founded in 2021 by healthcare experts behind Min Doktor, reports 20,000 active users with over 200 tons of collective weight loss.

The funding will support Yazen’s European expansion, with current operations in Sweden and soft launches in the Netherlands, Norway, and Spain, as well as pilot projects in the UK and Germany. Yazen employs healthcare professionals with dual certifications, reducing expansion costs by avoiding local offices.

Yazen is profitable in Sweden, generating €18 million in annual recurring revenue and operating with a team of 150, half of whom are general practitioners. CEO Fredrik Meurling is optimistic about overcoming supply chain issues affecting GLP-1 drugs in Europe, predicting Yazen’s trajectory toward unicorn status as demand for digital obesity solutions grows.

References: Link to Sifted

Start your weight loss journey with Yazen today

Everything you need to do is to create an account and answer some questions about your health

Get Started
Get Started
Get Started

More news

Press release
Yazen Health closes €19.5M series A to drive global growth

Yazen Health has successfully closed an oversubscribed €19.5 million series A funding round to fuel its international expansion. This investment enables Yazen to enhance its pioneering obesity treatment model, combining modern weight loss medication with comprehensive lifestyle support.

News
Lasker~DeBakey Award 2024 for groundbreaking GLP-1 obesity research

Lasker~DeBakey Award 2024 for groundbreaking GLP-1 obesity research

News
Startups shifting to GLP-1s to tap into $150bn weight loss market

GLP-1 weight loss drugs like Wegovy are attracting startups and investors, aiming to tap into the projected $150bn market despite supply and reimbursement challenges